

ERS Virtual School Nebulisation of drugs for treatment of respiratory infections and disease

25 February 2025 Online



Organised in collaboration with the Horizon 2020 FAIR project.

Tuesday, 25 February 2025

09:00–09:10	Welcome and introduction - M. Baldry & R. MacLoughlin
	Session 1 – Concepts / Basics / demonstrations in drug nebulisation
	Chairs: M. Baldry & R. MacLoughlin
09:10-09:30	Overview of inhaled drug delivery – E-S. Suh
09:30-09:50	Inhaled medicine formulations – B. Forbes
09:50-10:10	Introduction to aerosol and inhalation devices – B. Müllinger
10:10–10:25	Jet, ultrasonic nebuliser, vibrating mesh nebuliser: demo, pros & $cons - C$. Dantas
10:25-10:45	Discussion Q&A, quiz
10:45–11:15	Break
	Session 2 – Pre-clinical models to assess nebulisation effectiveness
	Chairs: N. Heuze-Vourc'h & J-C. Sirard
11:15-11:35	Challenges in assessing inhaled biologics in pre-clinical models – R. Vanbever
11:35-11:55	In vivo influenza pig model for inhaled vaccines development – E. Tchilian
11:55-12:15	In vitro human lung models to evaluate safety and efficacy of inhaled therapeutics – S. Constant
12:15–12:35	Discussion Q&A, quiz
12:35–13:35	Lunch



	Session 3 – Clinical development in nebulisation of biologics
	Chairs: A. Rojas Fernández, CE. Luyt
13:35–13:55	Inhaled antivirals – B. Horvat
13:55–14:15	Inhaled antibodies – A. Schnell
14:15–14:35	Discussion Q&A, quiz
14:35–15:05	Break
	Session 4 – Drug and biologic nebulisation in clinics
	Chairs: J. Li
15:05-15:20	Nebulised antibiotics in the clinic / clinical trials $-$ S. Ehrmann
15:20–15:35	Amikacin liposome inhalation in the clinic / clinical trials – P. Flume
15:35–15:50	Pulmozyme in the clinic / clinical trials – J. Laffey
15:50–16:05	Discussion Q&A
	Round table discussion – The successes and future of nebulised therapies
	Chairs: S. Ehrmann
16:05–16:10	Introduction of round table participants – S. Ehrmann
16:10–16:50	Discussion – JP Horcajada, M. Cazzola, N. Heuze-Vourc'h, K. Schwarz, P. Kuehl, O. Usmani
16:50–17:00	Wrap-up and closing remarks



This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 847786.